Latest Distributions News

ECS Botanics reports a third straight quarter of positive operating cash flow, driven by strong B2C growth and strategic international shipments to Germany and New Zealand.

Kingfish Limited’s portfolio endured a tough first quarter of 2026, with a 7.2% adjusted NAV decline amid Iran conflict-driven volatility. While a2 Milk’s expansion in China buoyed gains, shares in consumer-exposed names and tech-linked Vista Group plunged sharply.

MFF Capital Investments has updated its dividend distribution details for the half-year ending December 2025, confirming a fully franked 10-cent dividend payable in May and setting reinvestment plan prices at AUD 4.577.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

Diamond Infraco 1 Pty Ltd, backed by IFM Global Infrastructure Fund, has tabled an all-cash takeover offer for the remaining Atlas Arteria securities at A$4.75, rising to A$5.10 if a 45% stake is secured. The bid comes amid concerns over Atlas Arteria’s recent strategic pivot and operational underperformance.

AML3D has maintained a steady $2.2 million quarterly revenue run rate and secured $12.5 million in new orders during 3Q26, pushing its total orders for FY2026 to $29 million. The company is aggressively expanding its US manufacturing footprint and making initial inroads into UK and European defence markets.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

Barton Gold Holdings has reported exceptional high-grade gold assays up to 170 g/t at its Challenger project and strong drilling progress at Tunkillia, underpinning an advancing feasibility study and a robust cash balance of $13.3 million.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

Sarytogan Graphite Limited has upgraded its Central Graphite Zone resource, marking a key milestone with Measured classification and progressing its Definitive Feasibility Study. Meanwhile, copper exploration reveals promising anomalies, backed by fresh capital injections.

Western Yilgarn NL has reported a maiden discovery of high-grade gallium-tellurium mineralisation at its Ida Holmes Junction Project, alongside confirmation of extensive cobalt-nickel-copper-lead-scandium mineralisation continuity. The company also updated its substantial bauxite resource base in its March 2026 quarterly report.

De.mem Limited has extended its growth streak with record quarterly cash receipts of approximately $10.4 million, a 31% increase year-on-year, alongside positive operating cash flow of $504,000 for the March 2026 quarter.